COVID-19 rapid test Sofia

for nucleocapsid proteinsSARS-COV-2nasal

The Sofia SARS Antigen Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral flow technology in a sandwich design for qualitative detection of nucleocapsid protein from SARS-CoV-2. The Sofia SARS Antigen FIA, with the Sofia 2 and Sofia analyzers, provides automated and objective results in 15 minutes, allowing for testing of patients suspected of COVID-19/2019-nCoV in near-patient testing environments. Healthcare professionals can purchase the Sofia SARS Antigen FIA through select authorized distributors. Features & Benefits Rapid results to support efficient dispositioning of patients. Objective, accurate results Reliable results without cross-reactivity to seasonal coronaviruses. Dual work modes Adjusts to your volume fluctuations. Allows for significant throughput and batching of samples in READ NOW Mode. Easy to use Simple test workflow follows a similar format to CLIA-waived Sofia and Sofia 2 assays. Virena connection Provides automated tracking, data capture, government reporting, and exclusive disease mapping. Fluorescent technology with automated read Objective result that eliminates the subjectivity of a visual read. All necessary components included in kit Ready for use with Sofia 2 and Sofia for nasal swab procedure. Self-contained Test Cassette Clean, easy to use and dispose of. Sample type Direct nasal swabs Kit storage conditions Room temperature (15°C to 35°C / 59°F to 86°F) Controls Positive and negative, included in kit PPA 96.7% NPA 100% Shelf life 24 months from date of manufacture CLIA complexity Waived*